Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Net Margin came in at 42.66% in Q1 2026, up 254.0% YoY from 12.05% in Q1 2025, and up 4.43% on a QoQ basis from 40.85% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 9 years of Net Margin data on file, last reported at 42.66% in Q1 2026.
- Quarterly Net Margin rose 254.0% year-over-year to 42.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.69% (up 178.0% YoY) and the FY2025 annual result came in at 38.03%, up 470.0% from the prior year.
- Net Margin advanced to 42.66% in Q1 2026, from 40.85% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 42.66% in Q1 2026 to a low of 29.96% in Q3 2023.
- A 5-year average of 31.55% and a median of 35.57% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin tumbled 6970 bps — and 2024, when it surged 6406 bps.
- Tracing CPRX's Net Margin over 5 years: stood at 41.92% in 2022, then tumbled by 63 bps to 15.41% in 2023, then surged by 156 bps to 39.44% in 2024, then gained by 4 bps to 40.85% in 2025, then rose by 4 bps to 42.66% in 2026.
- The last three Net Margin figures came in at 42.66% (Q1 2026), 40.85% (Q4 2025), and 35.57% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 42.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.66% |
| Dec 31, 2025 | 40.85% |
| Sep 30, 2025 | 35.57% |
| Jun 30, 2025 | 35.55% |
| Mar 31, 2025 | 40.12% |
| Dec 31, 2024 | 39.44% |
| Sep 30, 2024 | 34.10% |
| Jun 30, 2024 | 33.24% |
| Mar 31, 2024 | 23.63% |
| Dec 31, 2023 | 15.41% |
| Sep 30, 2023 | -29.96% |
| Jun 30, 2023 | 37.92% |
| Mar 31, 2023 | 34.64% |
| Dec 31, 2022 | 41.92% |
| Sep 30, 2022 | 39.74% |
| Jun 30, 2022 | 40.70% |
| Mar 31, 2022 | 30.73% |
| Dec 31, 2021 | 24.30% |
| Sep 30, 2021 | 28.73% |
| Jun 30, 2021 | 33.50% |